Physician profile
Howard Kerstein
NPI 1184607012
$19,046.23
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,840.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,005.87 | 2019 | |
| Lilly USA, LLC | $3,609.59 | 2019-2020 | |
| Novo Nordisk INC | $2,156.20 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,988.29 | 2019-2020 | |
| Mannkind Corporation | $206.35 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $205.53 | 2019 | |
| Abbvie INC. | $193.68 | 2019-2020 | |
| Insulet Corporation | $83.35 | 2019 | |
| Merck Sharp & Dohme LLC | $79.81 | 2019-2020 | |
| Amgen INC. | $65.26 | 2019 | |
| Sanofi-Aventis U.S. LLC | $63.26 | 2019 | |
| Horizon Therapeutics Plc | $51.75 | 2019-2020 | |
| Lifescan, INC. | $49.09 | 2019 | |
| Abbott Laboratories | $46.59 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $37.71 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.97 | 2019-2020 | |
| Gilead Sciences, INC. | $26.07 | 2019 | |
| Ibsa Pharma INC. | $22.31 | 2019 | |
| Senseonics, Incorporated | $22.00 | 2019 | |
| Becton, Dickinson and Company | $17.49 | 2019 | |
| Corcept Therapeutics | $15.31 | 2019 | |
| Aytu Biopharma, INC. | $14.55 | 2019 | |
| Shire North American Group INC | $13.75 | 2019 | |
| Dexcom, INC. | $13.54 | 2020 |
Research and ownership
$1,171.93 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Kerstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.